PMID: 9174179Jun 1, 1997Paper

Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives

Antimicrobial Agents and Chemotherapy
M BabaT Okamoto

Abstract

We have found novel piperazinyloxoquinoline derivatives to be potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in both acutely and chronically infected cells. 8-Difluoromethoxy-1-ethyl-6-fluoro-1,4-didehydro-7-[4-(2-met hoxyphenyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid (K-12), the most potent congener of the series, completely inhibited HIV-1 replication in acutely infected MOLT-4 cells at a concentration of 0.16 to 0.8 microM without showing any cytotoxicity. The compound completely suppressed tumor necrosis factor alpha (TNF-alpha)-induced HIV-1 expression in latently infected cells (OM-10.1) and constitutive viral production in chronically infected cells (MOLT-4/III(B)) at a concentration of 0.8 microM. K-12 could also inhibit HIV-1 antigen expression in OM-10.1 and MOLT-4/III(B) cells at this concentration. Northern blot analysis revealed that K-12 selectively prevented the accumulation of HIV-1 mRNA in MOLT-4/III(B) and TNF-alpha-treated OM-10.1 cells in a dose-dependent fashion. It was not inhibitory to HIV-1 Tat or the cellular transcription factors NF-kappaB and Sp1, suggesting that the piperazinyloxoquinoline derivatives are a group of HIV-1 transcription inhibitors w...Continue Reading

References

Feb 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·T KalebicA S Fauci
Jan 1, 1991·Annual Review of Microbiology·B R Cullen
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M RoedererL A Herzenberg
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·H E GendelmanM A Martin
Aug 1, 1988·Journal of Virological Methods·R PauwelsE De Clercq
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L OsbornG J Nabel
Apr 1, 1989·AIDS Research and Human Retroviruses·T OkamotoK Shimotohno
Jan 1, 1987·AIDS Research and Human Retroviruses·L RatnerF Wong-Staal
Nov 21, 1995·Proceedings of the National Academy of Sciences of the United States of America·J N GnabreR C Huang
Apr 1, 1995·Clinical Microbiology Reviews·E De Clercq
May 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·H J ProchaskaB Polsky
May 23, 1995·Proceedings of the National Academy of Sciences of the United States of America·D W LeungS Bursten
Jan 1, 1994·Annual Review of Biochemistry·K A Jones, B M Peterlin
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M C HsuM J Potash
Jan 1, 1996·AIDS Research and Human Retroviruses·J W CritchfieldT M Folks

❮ Previous
Next ❯

Citations

Feb 27, 2003·Antimicrobial Agents and Chemotherapy·Cristina ParolinGiorgio Palù
Mar 12, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Valeria FamigliniRomano Silvestri
Feb 16, 2018·Current Medicinal Chemistry·Hamada H H MohammedEl-Shimaa M N Abdelhafez
Oct 16, 2004·Expert Review of Anti-infective Therapy·Jim A Turpin
Nov 19, 2008·Antimicrobial Agents and Chemotherapy·Beatrice MercorelliArianna Loregian
Nov 15, 2013·Journal of Virology·Irene GuendelFatah Kashanchi
Mar 18, 1999·Antiviral Chemistry & Chemotherapy·D DaelemansE De Clercq
Mar 24, 2011·Future Medicinal Chemistry·Oriana TabarriniVioletta Cecchetti
Jan 1, 2012·Biology·Guillaume Mousseau, Susana Valente
Oct 23, 2018·Infectious Disorders Drug Targets·Muhammad Faraz AnwarSyed Ali
Jul 13, 2006·Journal of Biomolecular Screening·Mirjam-Colette KempfOlaf Kutsch
Aug 18, 2012·Advances in Virology·Luna LiBrian Wigdahl
Jan 1, 2010·Acta Crystallographica. Section E, Structure Reports Online·S NatarajanP L Nilantha Lakshman
Feb 25, 2005·Molecular Pharmacology·Dirk DaelemansErik De Clercq
Oct 9, 2002·Medicinal Research Reviews·Erik De Clercq
Sep 10, 2005·The Journal of Antimicrobial Chemotherapy·Miguel StevensChristophe Pannecouque
Nov 15, 2011·AIDS Research and Human Retroviruses·Ann Florence B Victoriano, Takashi Okamoto
Oct 6, 2000·Journal of Medicinal Chemistry·V CecchettiG Palu'
Nov 5, 1999·Journal of Molecular Biology·J Karn
Oct 16, 2004·Journal of Medicinal Chemistry·Oriana TabarriniArnaldo Fravolini
Jul 17, 2021·Fundamental & Clinical Pharmacology·Rania AlaaeldinMoustafa Fathy
Jul 8, 2009·Bioorganic & Medicinal Chemistry·Fernanda da C SantosMaria C B V de Souza

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.